Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jan 21.
doi: 10.1007/s11030-024-11085-3. Online ahead of print.

Nano-sized heterogeneous photocatalyst Fe3O4@V/TiO2-catalyzed synthesis and antimycobacterial evaluation of 2-substituted benzimidazoles

Affiliations

Nano-sized heterogeneous photocatalyst Fe3O4@V/TiO2-catalyzed synthesis and antimycobacterial evaluation of 2-substituted benzimidazoles

Lijian Bao et al. Mol Divers. .

Abstract

The 2-substituted benzimidazole has emerged as a promising heterocyclic compound in the field of drug design. In pursuit of more sustainable photocatalysts for 2-substituted benzimidazole synthesis, the method for coating Fe3O4 with V-doped TiO2 was presented. On the base of characterizing composition, morphology, and properties, the prepared nano-sized Fe3O4@V/TiO2 composites were used as a heterogeneous photocatalyst to catalyze the synthesis of 2-substituted benzimidazoles under light. The photocatalyst Fe3O4@V/TiO2 composites showed the enhanced photocatalytic activity compared to no V-doped Fe3O4@TiO2, being able to yield various 2-substituted benzimidazoles in moderate to good yield with recyclability and stability. A possible photocatalysis mechanism was investigated. It was evident that holes, singlet oxygen, and ·O2̄ radical played important roles in the synthesis of 2-substituted benzimidazole. Moreover, some of the obtained products were demonstrated excellent antibacterial activity.

Keywords: Antibacterial activity; Benzimidazole; Fe3O4@V/TiO2; Nanocomposites; Photocatalysis; Synthesis.

PubMed Disclaimer

Conflict of interest statement

Declarations. Competing interest: The authors declare no competing interests.

Similar articles

References

    1. Konduri S, Prashanth J, Krishna VS, Sriram D, Behera JN, Siegel D, Rao KP (2020) Design and synthesis of purine connected piperazine derivatives as novel inhibitors of mycobacterium tuberculosis. Bioorg Med Chem Lett 30:127512. https://doi.org/10.1016/j.bmcl.2020.127512 - DOI - PubMed
    1. Zumla A, Nahid P, Cole ST (2013) Advances in the development of new tuberculosis drugs and treatment regimens. Nat Rev Drug Discov 12:388–404. https://doi.org/10.1038/nrd4001 - DOI - PubMed
    1. Da Silva PEA, Palomino JC (2011) Molecular basis and mechanisms of drug resistance in Mycobacterium tuberculosis: classical and new drugs. J Antimicrob Chemother 66:1417–1430. https://doi.org/10.1093/jac/dkr173 - DOI
    1. Aslan EK, Han Mİ, Krishna VS, Tamhaev R, Dengiz C, Dogan SDD, Lherbet C, Mourey L, Tønjum T, Gündüz MG (2022) Isoniazid linked to sulfonate esters via hydrazone functionality: design, synthesis, and evaluation of antitubercular activity. Pharmaceuticals 15:1301. https://doi.org/10.3390/ph15101301 - DOI
    1. Shi Y, Jiang K, Zheng R, Fu J, Yan L, Gu Q, Zhang Y, Lin F (2019) Design, microwave-assisted synthesis and in vitro antibacterial and antifungal activity of 2,5-disubstituted benzimidazole. Chem Biodivers 16:e1800510. https://doi.org/10.1002/cbdv.201800510 - DOI - PubMed

LinkOut - more resources